



Invesco Small Cap Growth Portfolio

Quarterly Performance Commentary

CUSIPS: RZ:76222X786 RA:76222X794

Investment objective

The portfolio seeks long-term growth of capital.

Portfolio management

Juan R. Hartsfield, Clay Manley

Management is that of the underlying fund.

Portfolio information

Total net assets \$14,176,698

Total number of holdings 118

Holdings shown are that of the underlying fund.

Top equity holdings

% of total net assets

Repligen	1.75
Q2 Holdings	1.60
Bio-Techne	1.38
HealthEquity	1.32
TransDigm	1.32
Aspen Technology	1.25
Chemed	1.25
CoreSite Realty	1.25
Sarepta Therapeutics	1.22
Realpage	1.19

Holdings are that of the underlying fund, subject to change and are not buy/sell recommendations.

Top contributors

% of total net assets

1. Repligen	1.75
2. Aspen Technology	1.25
3. Catalent	1.16
4. MarketAxess	1.01
5. Fair Isaac	1.18

Data shown is that of the underlying fund.

Top detractors

% of total net assets

1. 2U	0.44
2. Aerie Pharmaceuticals	0.42
3. Intersect ENT	0.63
4. SailPoint Technologies	0.59
5. Agios Pharmaceuticals	0.79

Data shown is that of the underlying fund.

Portfolio commentary provided is based on the underlying fund.

Market overview

- Though the S&P 500 Index posted a modest gain of 4.30% for the second quarter, the US stock market experienced increased volatility.
- Bond yields and oil prices fell in May as investors weighed the impact of the ongoing US/China trade war and potential for new tariffs on Mexican imports.
- Additionally, data showed slowing in the US and global economies.
- The Federal Reserve left interest rates unchanged at its June Federal Open Market Committee meeting, but signaled a less restrictive stance, leading some investors to anticipate a future rate cut.

Performance highlights

- The portfolio's Class RZ units at net asset value (NAV) posted a gain for the quarter and outperformed the Russell 2000 Growth Index. (Please see the investment results table on page 2 for portfolio and index performance.)
- Relative to the index, stock selection in the health care, financials, communication services, consumer staples, real estate, materials and energy sectors were all key contributors.
- Conversely, stock selection and an underweight in the industrials sector was the leading detractor from relative return. Stock selection in the consumer discretionary and information technology (IT) sectors also detracted.

Contributors to performance

- **Repligen**, a Massachusetts-based biotechnology company, experienced stronger-than-expected broad-based organic growth. **Repligen** also benefited from a favorable reaction to the announced acquisition of C Technologies (not a fund holding), which will expand its direct portfolio of products and add analytical systems to measure protein concentration in the manufacturing process.
- **MarketAxess**, a financial technology company, rallied on strong organic growth of electronic trading volumes, which led to positive earnings estimate revisions across all of its portfolios.
- **Catalent** benefited from a favorable response to the announcement of a deal to acquire Paragon (not a fund holding), which will likely accelerate **Catalent's** long-term growth and margin profile by diversifying its offerings away from lower growth markets into higher growth areas like outsourced manufacturing markets for gene/cell therapy.

Detractors from performance

- Health care equipment company **Intersect ENT** struggled during the quarter as the launch of its new product, Sinuva, stalled due to continued reimbursement issues. These issues also negatively affected the company's core product portfolio. The CEO also resigned unexpectedly, which magnified the negative impact on the stock.
- **Aerie Pharmaceuticals** launched Rocklatan and Rhopressa, which are designed to lower eye pressure in patients with open-angle glaucoma and ocular hypertension, but the launch fell short of expectations. We view the dynamics driving the weaker-than-expected launch as temporary.
- **Agios Pharmaceuticals** faced weaker-than-expected first quarter revisions for its commercial franchise of IDH inhibitors for Acute Myeloid Leukemia. Additionally, the company suffered from fears that recent competitor data has led to a lower-than-expected share of new patients for **Agio**.

Positioning and outlook

- All positioning changes are based on our bottom-up stock selection process. Portfolio construction acts as a risk control and ensures alignment with small-cap market sector exposure within modest over- and underweights. Our long-term investment horizon leads to relatively low turnover.
- Our view is that the growth environment is slowing as the benefits of US tax stimulus and deregulations are being offset by higher interest rates, rising labor costs and trade pressures.
- In such an environment, true growth will likely remain scarce, and we believe the market will favor companies that can produce sustainable, above-average earnings and cash flow growth in spite of the economic cycle.

Investment results

Average annual total returns (%) as of June 30, 2019

Period	Class RZ units		Class RA units	Style-Specific Index
	Inception: 07/08/16		Inception: 07/08/16	Russell 2000 Growth Index
	Max Load 4.00%	NAV	NAV	
Inception	12.73	14.30	14.02	-
1 Year	-3.62	0.40	0.07	-0.49
Quarter	-0.40	3.76	3.65	2.75

The performance quoted is past performance and is not a guarantee of future results. Investment returns and principal value of an investment will fluctuate so that an account owner's units, when redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance data shown. For up-to-date month-end performance information please call 877 615 4116, or visit collegebound529.com. Performance figures reflect reinvested distributions of the underlying security and changes in net asset value (NAV). Performance shown at NAV for Class RZ units does not include applicable front-end sales charges, which would have reduced the performance. Class RA units have no sales charge; therefore, performance is at NAV. Returns less than one year are cumulative; all others are annualized. Index returns do not reflect any fees, expenses, or sales charges.

Index source: Invesco

Asset mix (%)

Domestic Common Stk	97.21
Int'l Common Stk	1.58
Cash	1.05
Other	0.16


Data shown is that of the underlying fund.

Expense ratios (%)

Class RZ units	0.73
Class RA units	0.99
Total annual asset-based fee per the current Program Description.	

The portfolio's positioning versus the

(% underweight/overweight)



Data shown is that of the underlying fund.

For more information you can visit us at collegebound529.com

Class RZ units and Class RA units are available only to certain investors who are residents of the State of Rhode Island. See the Program Description for more information. The underlying fund holdings are organized according to the Global Industry Classification Standard, which was developed by and is the exclusive property and service mark of MSCI Inc. and Standard & Poor's.

The Russell 2000[®] Growth Index is an unmanaged index considered representative of small-cap growth stocks. The Russell 2000 Index is a trademark/service mark of the Frank Russell Co. Russell[®] is a Trademark of the Frank Russell Co. An investment cannot be made directly in an index.

The S&P 500[®] Index is an unmanaged index considered representative of the US stock market. An investment cannot be made directly in an index.

About risk

Risks of the Underlying Holding

The risks of investing in securities of foreign issuers, including emerging markets, can include fluctuations in foreign currencies, political and economic instability, and foreign taxation issues.

Growth stocks tend to be more sensitive to changes in their earnings and can be more volatile.

Stocks of small and mid-sized companies tend to be more vulnerable to adverse developments, may be more volatile, and may be illiquid or restricted as to

resale.

The portfolio is subject to certain other risks. Please see the current Program Description for more information regarding the risks associated with an investment in the portfolio.

FOR RHODE ISLAND INVESTOR USE ONLY

NOT FDIC INSURED | MAY LOSE VALUE | NO BANK GUARANTEE

Before you invest, consider whether your or the beneficiary's home state offers any state tax or other state benefits such as financial aid, scholarship funds, and protection from creditors that are only available for investments in that state's qualified tuition program.

For more information about CollegeBound 529, contact your financial advisor, call 877-615-4116, or visit www.collegebound529.com to obtain a Program Description, which includes investment objectives, risks, charges, expenses, and other important information; read and consider it carefully before investing. Invesco Distributors, Inc. is the distributor of CollegeBound 529.

Note: Not all products available at all firms. Advisors, please contact your home office.

All data provided by Invesco unless otherwise noted.